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BETA THALASSEMIA-INDUCED OSTEOPOROSIS: EVALUATING 
CURRENT AND NOVEL THERAPEUTIC OPTIONS 
NATASHA KHULLAR 
ABSTRACT 
Osteopenia and/or Osteoporosis (OOS) is becoming an increasingly prevalent chronic 
disease among Beta Thalassemia Major (BTM) patients, especially now that life 
expectancy in these patients has considerably improved through regular blood 
transfusions and iron chelation therapy. With several, complex genetic and acquired 
factors involved in its pathogenesis, coupled with the heterogeneity in the clinical 
response of BTM patients to different pharmacological agents, OOS has proven to be 
particularly difficult to treat. The great majority of treatment options currently available 
are not curative, but instead are aimed towards managing the symptoms and progression 
of the disease in patients. General preventative measures, such as iron chelation therapy 
and hormonal replacement therapy (HRT), are instrumental aspects of the treatment plan; 
however, the incredible complexity of OOS necessitates an individualized, 
multidisciplinary approach to management, with a principal therapy that is safe and 
effective in patients, and that is accompanied by these other supportive measures. This 
review, through a comprehensive analysis of current literature, includes data from 
randomized, placebo-controlled trials, double blind and observational clinical studies, and 
suggests optimal therapeutic interventions for first-line management of OOS. It also 
addresses treatment options for BTM patients in whom resistance to the recommended 
first-line therapy develops, or who display secondary endocrine conditions contributing 
	  	   vii 
to OOS. In addition to providing a current synopsis of OOS management and the 
potential of emerging treatment options, this analysis highlights some of the limitations 
of traditional therapies. In this way, the paper effectively illustrates the current status of 
TM-induced OOS; it describes what is or isn’t working, as well as underscores the 
diagnostic and therapeutic challenges continually faced by patients, researchers and 
clinicians.  
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INTRODUCTION 
 Beta-thalassemia major (BTM) is a hereditary blood disorder characterized by a 
reduction or abnormality in the synthesis of one or more of the beta globins involved in 
forming the hemoglobin tetramer (Galanello & Origa, 2010). Specifically, hemolysis and 
ineffective erythropoiesis due to these defective beta globins lead to the anemia that is 
characteristic of beta-thalassemia (Rund & Rachmilewitz, 2005) (Figure 1). According to 
Galanello and Origa (2010), approximately 1 in 100,000 people throughout the world 
exhibit symptoms annually, indicating that it is a fairly rare disease. The severe form of 
the disease can lead to ineffective erythropoiesis, growth retardation, pallor, severe 
anemia, jaundice, bone marrow expansion and skeletal deformity, iron overload and poor 
musculature (Galanello & Origa, 2010). Therefore, beta-TM patients usually require 
regular blood transfusions and iron-chelating therapy throughout their lives, beginning at 
a very young age (Galanello & Origa, 2010). Fortunately, over the last few decades, the 
survival and quality of life of TM patients has improved in response to these effective 
transfusion and iron chelation therapies (Galanello & Origa, 2010). However, with 
increased life expectancy due to these therapies, a new series of symptoms have arisen 
and become reason for universal concern. Despite adequate transfusion and iron chelation 
therapy, osteopenia and/or osteoporosis (OOS), which is characterized by reduced bone 
mass density (BMD) in children and young adults alike, persists as a prominent cause of 
morbidity (De Sanctis et al., 2013). According to De Santis et al. (2013), the incidence of 
osteoporosis can range from 13.6% to 50%, often affecting even the most well treated 
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TM patients, while an additional 45% of patients have been shown to be affected by 
osteopenia. 
 
Figure 1. Pathophysiology of Hemolysis and Ineffective Erythropoeisis. A long chain 
of events within the erythrocytes leads to their accelerated peripheral apoptosis. This 
accelerated destruction is associated with an increase in the extracellular exposure of 
phosphatidylserine, which is detected as a signal by activated macrophages, as well as an 
increase in the amount of phosphatidylserine within the bone marrow for thalassemia 
patients. Figure taken from (Rund & Rachmilewitz, 2005).  
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Pathogenesis 
The etiology and pathogenesis of reduced BMD in TM-induced osteoporosis are 
multifactorial. In other words, both genetic factors as well as factors accumulated over 
time contribute to the increasing demineralization of bone in thalassemia patients 
(Galanello & Origa, 2010) (Table 1). 
Table 1. Pathogenesis of TM-induced OOS. Genetic and acquired factors involved in 
reducing BMD in patients with beta-thalassemia. Adapted from (Giusti et al., 2016). 
Genetic factors that 
predispose to reduced 
BMD 
Acquired factors that contribute to reduced BMD 
 Primary factors Secondary factors 
Collagen Type Ia1 
(COLIA1) Gene (Sp1 
Polymorphism) 
Bone marrow expansion 
(ineffective erythropoiesis) 
Endocrine:  
Hypogonadism  
Growth hormone and 
insulin-like growth 
factor-1 deficiency 
Diabetes mellitus 
Vitamin D receptor (FokI 
and BsmI polymorphisms) Iron overload 
Nutritional: 
Vitamin D deficiency 
Zinc, Vitamin C, 
Vitamin K 
deficiencies 
 Reduced physical activity 
Renal tubular disease (renal 
phosphate wasting and 
hypercalciuria) 
Iron chelators 
Sarcopenia 
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Acquired Factors 
 There is evidence that conditions, such as thalassemia, anemia, hypoxemia and 
impaired GH/IGF-1 axis can lead to significant negative effects on growth and puberty 
(Scacchi et al., 2008). According to a study by Scacchi et al. (2008), which explored the 
potential role of GH and IGF-I levels in the pathogenesis of TM-induced OOS, the 
inability to successfully secrete GH as well as having reduced serum IGF-I levels may 
contribute to femoral demineralization in thalassemia patients. Alternatively, 
endocrinopathies due to iron overload, which are possible in many organs of the 
endocrine system despite iron chelation therapy, could also contribute to the pathogenesis 
of TM-induced OOS. For example, one study by Chatterjee and Katz (2000) analyzed 
thalassemia patients with varying degrees of low BMD and disease severity. The authors 
observed that TM patients who had been diagnosed with severe OOS concomitantly 
presented with irreversible damage to their hypothalamo-pituitary axis, due to significant 
iron overload and endocrine organ damage (Chatterjee & Katz, 2000). In comparison, the 
authors found a correlation between the remaining TM patients with minor OOS and 
hypogonadotrophic hypogonadism (Chatterjee & Katz, 2000). Evidently, 
endocrinopathies play at least some role in the onset and progression of TM-induced 
OOS. 
 
Genetic Factors 
Notably, genetic defects are also important contributing factors in the 
pathogenesis of TM-induced osteoporosis. In particular, the collagen type I A1 
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(COLIA1) gene is a fundamental candidate gene that may be responsible for the 
regulation of the pathogenetic process of osteoporosis (Hamed et al., 2011). This gene 
encodes for type I collagen, which is typically abundant and critical for bone formation 
and preservation (Hamed et al., 2011). Hamed et al. (2011) analyzed the distribution of 
the COLIA1 polymorphism in relation to BMD at the spine and femur of TM patients 
and arrived at the conclusion that there is a strong correlation between a polymorphism at 
the Sp1 site of the gene and severe osteoporosis or pathologic fractures in the tested 
regions. With this in mind, it will be vital for clinicians to detect this mutation as early as 
possible for there to be any hopes of prevention; genotyping and identifying base 
substitutions at the Sp1 binding site on the COLIA1 gene in the early years of childhood 
that could help prevent significant osteoporosis in individuals with beta-TM (Guzeloglu-
Kayisli et al., 2008). Comparatively, another possible factor for predisposition to 
osteoporosis and increasingly low BMD is the vitamin D receptor (VDR) polymorphism 
(Haider et al., 2011). According to Haider et al. (2011), a reduction in osteoblast function 
leads to decreased bone formation, partly as a result of their inability to produce the 
protein osteocalcin, as well as an increase in osteoclast activity and augmented bone 
resorption. This phenomenon is thought to occur through a systemic pathway involving 
two mediating cytokines: osteoprotegerin (OPG) and receptor activator of nuclear factor 
kappa B ligand (RANKL) (Pietrapertosa et al., 2009). Another study (Salah et al., 2010) 
that was performed examined levels of OPG and OPG/RANKL. They found that patients 
with documented thalassemia-associated OOS had significantly lower levels of OPG and 
OPG/RANKL ratio compared to thalassemia patients with standard BMD. This suggests 
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that the OPG/RANKL pathway may be important for the activation and proliferation of 
osteoclast precursors and could potentially be used as a screening marker for OOS in 
thalassemia patients (Salah et al., 2010). 
 
Diagnostic Measures 
According to Voskaridou et al. (2014), osteopenia is defined as a BMD T-score 
between -1 and -2.5, where T-score refers to the “number of standard deviations (SD) that 
a patient’s bone mass is above or below the mean peak bone mass for a 30-year-old 
healthy woman.” In comparison, osteoporosis is defined as a BMD T-score that is less 
than -2.5 and a normal BMD value is when a T-score is determined to be over -1.0 
(Voskaridou et al., 2014). Since BTM patients can develop OOS and is at risk of bone 
fractures at any point in their lifetimes, it is important for clinicians to measure the BMD 
in a patient regularly.  
The most commonly utilized and reliable way to measure BMD in BTM patients 
is Dual Energy X-ray Absorptiometry (DEXA), a specialized, non-invasive form of x-ray 
technology that measures bone mass at the hip, femoral neck, lumbar spine and forearm 
of a human being (Gordon et al., 2014). While the lumbar spine is a preferred site for 
DEXA assessment of BMD in children and adolescents, the total hip and femur are 
preferred for adults (Gordon et al., 2014). In addition, a recent longitudinal study 
suggests that the femoral neck is the best site to achieve well-defined measurements 
when evaluating patients over a long period of time (Wong et al., 2014). Finally, it is 
notable that DEXA has been found to be a preferred method for initial OOS screening 
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assessment among elderly TM patients (Nayak et al., 2009). Specifically, researchers 
conducted a multivariable logistic regression analysis surveying a large population of 
osteoporotic patients, aged 60 years or older, on their screening test preferences (Nayak 
et al., 2009). Options included DEXA, the Risk Assessment Tool, Heel Quantitative 
Ultrasound or no test preference at all (Nayak et al., 2009). Interestingly, Dr. Nayak and 
his team found that the majority of respondents preferred DEXA as an initial osteoporosis 
screening assessment (Nayak et al., 2009) (Figure 2).  
 
Figure 2. Initial Osteoporosis Screening Preference of Older Adults. The distribution 
of osteoporosis screening preferences selected by adults ≥ 60 years old is shown. Test 
options included DEXA, Risk Assessment Tool, Heel Quantitative Ultrasound, and 
individuals were given the option to select No Test Preference. Figure taken from (Nayak 
et al., 2009). 
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Specific Aims 
Unfortunately, no individual pathogenetic mechanism has been determined at this 
time to be the universal target for thalassemia-associated OOS therapy. Several studies 
suggest that the etiology and pathogenesis of TM-induced osteoporosis is multifactorial. 
Therefore, both genetic and factors developed throughout life are involved in the 
demineralization of bone for thalassemia patients. In addition, TM and OOS are highly 
heterogeneous within and between patients, not only in pathogenesis, but also in response 
to various therapies. It is highly probable that the factors contributing to OOS 
in thalassemia intermedia (TI), which is a minor form of the homozygous disease, despite 
generally overlapping with those of thalassemia major (TM), have a different emphasis in 
regards to bone deformation and complications. These differences contribute to making 
the search for universal treatment difficult. Since extensive research has been published 
on the overall safety and efficacy of pharmaceutical agents, and considering the several 
new drugs that are currently in different stages of clinical testing, a comprehensive 
analysis would benefit patients and clinicians alike. Accordingly, the goal of this thesis is 
to present a comprehensive review assessing the important prescribing factors that 
patients and clinicians should be aware of, such as efficacy, potency and safety, when 
considering novel therapeutic options for thalassemia-associated osteoporosis. Another 
hope is that this manuscript will lead to a greater understanding of the complex 
mechanisms that contribute to OOS pathogenesis as well as emphasize the significance of 
a multidisciplinary approach in the management of OOS, specifically through risk-benefit 
analyses of many current and potential disease therapies.  
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CURRENT THERAPEUTIC OPTIONS 
Many non-surgical therapeutic options, such as analgesic drug intervention or the 
use of antiresorptive pharmacological agents, nutritional dietary control, and iron 
chelation therapy, currently exist for patients with TM-induced OOS. In the following 
sections, a comprehensive analysis of the literature and clinical studies available on each 
of these therapies is provided. 
 
Preventative Measures 
Osteopenia and osteoporosis are increasingly being discovered as patients with 
BTM live longer (Jensen et al., 1998). One study found that among 82 BTM patients, 
51% older than 12 years exhibited osteoporosis (Jensen et al., 1998). Since OOS is fairly 
prevalent among older TM patients, it is advisable that clinicians search for early signs of 
bone-related endocrinopathies in younger BTM patients who have not yet presented with 
severe TM-induced OOS. Undoubtedly, early detection of the disease and its risk factors 
is key to preventing future bone loss in patients. Through the adjustment of certain 
lifestyle activities and habits, BTM patients can significantly reduce the risk of bone 
fractures, as well as the severity of symptoms associated with the progression of OOS.  
Considering the plethora of symptoms and endocrinopathies that can develop 
concomitantly in patients with BTM-induced OOS, it is important to use a 
multidisciplinary approach in management of the disease. General, preventative measures 
for OOS include: a healthy diet, sufficient calcium and vitamin D intake, regular iron 
chelation therapy to prevent iron toxicity in the bone, annual BMD exams commencing 
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pre-menarche or before puberty, and the appropriate management of secondary or pre-
existing endocrine complications, such as diabetes mellitus, hypogonadism, 
hypothyroidism and growth hormone (GH) deficiency (Giusti et al., 2016). It is vital that 
BTM patients also avoid harmful lifestyle factors, such as smoking, excessive alcohol 
consumption and drug abuse, as these activities have the potential to accelerate organ 
damage (Giusti et al., 2016). 
Importantly, BTM patients should ensure that they do not exceed daily 
recommended calcium intake. The recommended dietary calcium intake is between 700 
and 1200 mg daily, depending on the age and physiology of an individual (Ross et al., 
2011). According to one study, an increased risk of kidney stones, myocardial infarctions 
and the development of cardiovascular disease may be attributed to calcium supplements 
(Bolland et al., 2010). Although this data has yet to be verified by additional research, 
Borgna-Pignatti and Gamberini (2011) advise that BTM patients use calcium citrate 
instead of calcium carbonate, as well as add magnesium citrate in order to reduce the risk 
of kidney stones. Nonetheless, clinicians should remain cautious and monitor urinary 
calcium output in addition to dietary intake regularly (Borgna-Pignatti & Gamberini, 
2011). 
Finally, clinicians should always encourage physical activity in their BTM 
patients. Due to complications of the disease and/or overprotective measures by family, 
BTM patients tend to exercise less than recommended (Voskaridou et al., 2014). 
However, physical activity can actually lead to a positive, osteogenic effect in patients 
(Giusti et al., 2016). For example, a specific study by Lane et al. (1986) assessed the bone 
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composition and BMD of athletes who had a long-term history of long-distance running. 
In comparison to a control group of non-athletic adults, the authors found that the athletes 
exhibited a greater BMD at the lumbar spine (Lane et al., 1986). Therefore, regular 
physical activity should be encouraged in BTM patients as a supportive, secondary 
method to prevent or decrease the rate of deterioration of BMD. Conversely, BTM 
patients should not engage in heavy-lifting, especially if they have been diagnosed with 
severe OOS and have a history of bone fractures, as this activity would put patients at a 
greater risk for vertebral bone fractures (Giusti & Bianchi, 2015). 
 
Vitamin D Supplementation 
Vitamin D is required for the successful functioning of many physiological 
processes in the human body, including regulation of the immune and musculoskeletal 
system through effects on bone mineralization, and intestinal calcium absorption 
(Nakavachara & Viprakasit, 2013). According to a study conducted in 2011, deficiency 
in vitamin D is correlated with reduced BMD in children (Pirinççioğlu et al., 2011). It has 
also been correlated with an increased risk of bone fractures and falls in older BTM 
patients (Bischoff-Ferrari, 2014).  
The incidence of vitamin D deficiency (when 25(OH)D is concentration is less 
than 20 ng/mL) and insufficiency (when 25(OH)D concentration is between 20 and 30 
ng/mL) has been found to be quite high in BTM patients universally, even though some 
of these patients inhabit regions that are exposed to adequate sunshine throughout the 
year and most have fair access to vitamin D prescriptions (Fung et al., 2011). This data 
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suggests that BTM patients present with additional factors, at least in comparison to the 
general population, that contribute to vitamin D deficiency (Fung et al., 2011). These 
variables might include chronic liver disease, iron overload due to frequent blood 
transfusions, and other, secondary endocrine disorders (Wood et al., 2008).  
While sufficient research testing the correlation between vitamin D 
supplementation and improvement in BMD and/or fall risk for BTM patients in particular 
is still needed, one study by Bischoff-Ferrari et al. (2009) explored vitamin D’s effects on 
the elderly population. This meta-analysis specifically evaluated eight randomized, 
controlled trials involving elderly subjects (without TM) in order to determine if 
supplemental and active forms of vitamin D with or without calcium are effective in 
preventing falls in people aged 65 years or older (Bischoff-Ferrari et al., 2009). 
According to the researchers’ findings, fall prevention started to occur when individuals 
were given a vitamin D3 (cholecalciferol) dose of 700 IU daily (Bischoff-Ferrari et al., 
2009) (Figure 3). The data in Figure 3 indicate that individuals would need to achieve a 
serum 25(OH)D concentration of about 60 nmol/l in order for there to be a noteworthy 
reduction in the risk of falls (Bischoff-Ferrari et al., 2009).  
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Figure 3. Effects of Vitamin D Dose and 25(OH)D Concentrations on Fall 
Prevention. The effect sizes, which represent the pooled results of three trials, are shown 
as circles in these graphs, and the errors bars represent 95% confidence intervals. A 
trendline follows the effect sizes and reveals that the benefit of vitamin D in the 
prevention of falling started at a dose of 700 IU daily. Figure taken from (Bischoff-
Ferrari et al., 2009). 
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Lastly, even though additional studies are needed to focus specifically on the 
effects of vitamin D supplementation on bone fracture risk in BTM patients, many of 
these patients are currently using vitamin D replacement and have not reported any 
significant adverse effects (Voskaridou & Terpos, 2004). However, the ideal dosage for 
BTM patients to maintain a sufficient level of serum 25(OH)D with cholecalciferol is not 
yet defined. These data indicate that additional research studies are needed, and that this 
option should not be considered as the single, primary line of treatment for BTM-induced 
OOS (Bischoff-Ferrari, 2014). In any event, since the pathogenesis of OOS is 
multifactorial, and since it is at least apparent that vitamin D deficiency plays a role in the 
progression of OOS, levels of Vitamin D should be monitored and deficiencies in BTM 
patients should be addressed by clinicians as soon as they are discovered. 
 
Iron Chelation Therapy 
Although the pathogenesis of TM-induced OOS remains unclear, it has been 
suggested that iron toxicity is a strong contributor to the progression of the disease 
(Haidar et al., 2011). Therefore, an effective iron chelator could theoretically help prevent 
the development of OOS and reduce the risk of bone fractures in TM patients. 
While most studies focus on the effects of iron chelation on the liver and heart, 
one study by Casale et al. (2014) explored the effects of deferasirox (DFX), an iron 
chelation therapy, on BTM patients with OOS. The authors of the study found that 
patients who were treated with deferasirox for a median period of 6.5 years did not 
exhibit a significant change in the incidence of common TM-induced endocrinopathies 
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(Casale et al., 2014). Consequently, this data suggests that DFX plays a preventative role 
in TM patients, since new endocrinopathies did not appear throughout the study (Casale 
et al., 2014). 
A more recent study by Poggi et al. (2016) examined adult TM patients who had 
followed a particular type of iron chelation therapy (deferasirox, deferiprone, 
deferoxamine or a combination of deferiprone and deferoxamine) for at least five years. 
This retrospective, longitudinal study predominantly aimed to compare the long-term 
effects of the various iron chelators on their development or retrogression of OOS and 
other endocrinopathies, i.e. diabetes mellitus, hypogonadism, hypothyroidism (Poggi et 
al., 2016). Using DEXA, BMD was measured for each subject every 18 months for 5 
years (Poggi et al., 2016). As a result of the study, Poggi et al. (2016) interestingly found 
that deferasirox (DFX) was the only iron chelator in the study that led to a significant 
decrease in the prevalence of OOS after the total five years of therapy, apparent after only 
18 months of treatment with the agent (Figure 4).  
	  16 
 
Figure 4. Prevalence of Osteoporosis in TM patients on Different Iron Chelators. 
The prevalence of osteoporosis was determined at three different measurement points, at 
baseline, after 18 months of chelation, and after 36 months of chelation therapy. 
Osteoporosis was determined using measurements of BMD at the lumbar spine or 
femoral neck. Figure taken from (Poggi et al., 2016). 
 
According to Poggi et al. (2016), deferasirox effectively contributed to increasing BMD 
in patients and was shown to not only act as a protective measure against the 
development of new endocrinopathies, but also actually reverse the pathology in some of 
the patients who already exhibited baseline disease in the study (Figure 5). Specifically, 
when patients with existing endocrinopathies at baseline were treated with deferasirox, 
one subject exhibited reversal of diabetes mellitus, another had hypothyroidism reversal, 
and two patients achieved reversal of hypogonadism (Poggi et al., 2016). Comparatively, 
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none of the patients on the other singular iron chelators were able to reverse any 
endocrinopathy (Poggi et al., 2016). 
 
 
Figure 5. Change in the Prevalence of Endocrinopathies. The measurements of 
endocrinopathies were taken after five years of treatment with each iron chelator. DFO, 
deferoxamine; DFP, deferiprone; DFX, derasirox. Figure taken from (Poggi et al., 2016). 
 
Hormonal Replacement Therapy 
Several human sex hormones and steroids are involved as mediators in the natural 
processes of bone remodeling, growth and metabolism. Since BTM patients often 
experience concomitant hypogonadism, hormonal replacement therapy (HRT) is 
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becoming an increasingly common, safe and effective method to prevent further bone 
mass reduction and reduce the risk of bone fractures in patients (Lasco et al., 2001).  
Many studies have explored the effects of HRT on patients with BTM-induced 
OOS. For example, Lasco et al. (2001) conducted a cross-sectional study in which 40 
patients were evaluated for BMD and bone turnover markers, using dual energy X ray 
absorptiometry (DEXA scan) at the femur and lumbar spine. The authors essentially 
aimed to compare these bone parameters in BTM patients without gonadal impairment to 
the levels present in BTM patients with concomitant secondary hypogonadotropic 
hypogonadism or gonadal dysfunction (Lasco et al., 2001). Trial subjects were evenly 
separated into two groups based on sex hormone levels; subjects were placed in either 
Group A, composed of 10 males and 10 females who had been treated with HRT, or 
Group B, composed of 10 males and 10 females who were untreated TM patients (Lasco 
et al., 2001). A third control group, Group C, consisted of 20 healthy subjects matched 
for age, sex, height and weight to the other participants (Lasco et al., 2001). As a result of 
the investigation, Lasco et al. (2001) found that, compared to the control group, all TM 
patients showed increased bone turnover and decreased BMD. Interestingly, BTM 
patients treated with HRT for hypogonadism exhibited OOS only at the lumbar level, 
while untreated BTM patients with hypogonadism presented OOS at both their lumbar 
and femoral neck regions (Lasco et al., 2001). Moreover, the authors discovered a 
significant, positive correlation between HRT duration and values of BMD (Lasco et al., 
2001). Vitally, this data suggests that hypogonadism is a substantial and important 
contributor to the development of severe OOS in TM patients, and that early diagnosis 
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followed by HRT could improve the density and quality of bone tissue in these 
individuals (Lasco et al., 2001). 
Delayed or arrested puberty is considered one of the most common endocrine 
complications in young BTM patients (Saka et al., 1995). In one study, El Beshlawy et al. 
(2008) evaluated and compared the effects of HRT and L-carnitine therapy on the 
pubertal development of thirty-two pre-adolescent BTM patients (14 males and 18 
females). Failure of puberty was observed in the majority of male subjects, while arrested 
puberty was observed in the majority of female subjects (El Beshlawy et al., 2008). 
Furthermore, all patients were diagnosed with hypogonadism, either in the form of 
gonadal hypogonadism or both pituitary and gonadal hypogonadism (El Beshlawy et al., 
2008). Although the study did not ultimately find a significant difference between the 
group given L-carnitine treatment and the HRT group, the authors did observe that 75% 
of the male subjects and 100% of the female subjects in the HRT group improved in 
pubertal staging (El Beshlawy et al., 2008). Evidently, these findings support the use of 
HRT as an effective therapy for pubertal BTM patients, in addition to its efficacy for 
adult patients with OOS. However, follow-up clinical studies and additional trials with 
larger cohorts of pre-adolescent BTM patients are warranted, especially considering that 
only three females in the HRT group of this study were able to reach the menarche stage 
and they are remain vulnerable to developing secondary amenorrhea (El Beshlawy et al., 
2008).  
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Bisphosphonates  
The increased bone resorption commonly observed in TM patients has justified 
the wide use of bisphosphonates (BPs), which are incredibly powerful inhibitors of bone 
resorption and osteoclast function, as the leading management option for BTM-induced 
OOS (Giusti et al., 2016). BPs effectively increase BMD, decrease bone turnover and 
decrease bone resorption, thereby reducing the risk of fragility fractures (Giusti et al., 
2016) (Figure 6).  
Although BPs are largely well tolerated, potential adverse events may limit their 
use in a subset of BTM patients. Possible short-term effects of therapy with BPs, 
especially for those administered orally like pamidronate, include upper gastroesophageal 
irritation, hypocalcemia, acute phase reaction, musculoskeletal pain, ocular inflammation 
(i.e. conjunctivitis, scleritis, etc.) and esophageal cancer (Kennel & Drake, 2009). While 
severe musculoskeletal pain and ocular inflammation are rarely observed in patients, an 
adverse effect involving the upper GI is the most frequently reported reason for patient 
intolerance to oral BPs (Kennel & Drake, 2009). Comparatively, the most commonly 
cited long-term adverse event due to therapy with BPs is jaw osteonecrosis (Kennel & 
Drake, 2009). Other potential long-term effects include atrial fibrillation, subtrochanteric 
femoral fractures, and bone turnover suppression (Kennel & Drake, 2009).  
Importantly, the association between the majority of these short-term and long-
term adverse effects and therapy with BPs has yet to be sufficiently tested in clinical 
trials. One study by Wysowski (2010), however, suggests that oral bisphosphonates be 
avoided over IV infusions or alternative treatments. This author particularly supports past 
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findings that TM patients have experienced concomitant gastrointestinal (GI) disorders 
due to long-term use (Wysowski, 2010). Nonetheless, additional, longitudinal studies 
would be pivotal to making progress with this therapeutic option, and follow-up 
assessments are needed for TM patients being treated with one of the BPs for greater than 
3 years. All things considered, it would also be advisable that TM patients currently using 
BPs as treatment for OOS avoid exceeding 2-3 years of drug usage, and think about 
incorporating intermittent periods of alternative treatment to reduce the risk of bone 
fractures or other, possibly severe adverse effects.  
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Figure 6. Effect of IV Bisphosphosphates on BMD. The mean percent changes of 
BMD at the lumbar spine (A) and femoral neck (B) after one year of treatment with BPs, 
through IV infusion, are shown. TM patients were administered zoledronic acid at a dose 
of 4 mg every 6 months, or 3 months, neridronate at a dose of 100 mg every 3 months, or 
placebo. LS-BMD, lumbar spine BMD; FN-BMD, femoral neck BMD. Figure taken 
from (Giusti et al., 2016). 
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Currently, pamidronate, neridronate, and zoledronic acid are the primary BPs 
continually being considered and tested as therapeutic options in the management of 
BTM-induced OOS (Giusti et al., 2016). Many randomized, controlled trials in TM and 
TI patients with OOS have shown that these agents yield significant, positive effects in 
comparison to recorded baseline or placebo measurements (Giusti et al., 2016). These 
studies have also indicated that BPs are generally safe and tolerable for TM patients, 
supporting their usage as a first-line therapy in OOS management (Forni et al., 2012) 
(Giusti et al., 2016). While pamidronate is particularly effective at increasing BMD at the 
lumbar spine, neridronate and zoledronic acid present the added advantage of decreasing 
bone and back pain in patients (Forni et al., 2012). Unfortunately, since most clinical 
studies to date have involved patients with diverse baseline traits, it is not yet possible to 
directly compare the three BPs. All things considered, however, neridronate and 
zoledronic acid should primarily be considered for treatment. 
In the following sections, the three primary bisphosphonates, pamidronate, 
neridronate and zoledronic acid, all of which are currently being used and studied as 
therapeutic options for BTM-induced OOS, are discussed. 
 
Pamidronate 
Pamidronate is a bisphosphonate that has been shown by several research studies 
to be very effective in the treatment of OOS in BTM patients (Voskaridou et al., 2003) 
(Kowsaryan & Zafari, 2016). However, the mechanism of action for pamidronate is still 
not completely clear. One study concluded that both pamidronate and zoledronic acid act 
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by increasing the activity of primary osteoblasts to produce OPG while simultaneously 
preventing osteoclast activity through the inhibition of RANKL (Viereck et al., 2002). 
However, another study published in the same year seems to contest this proposed 
mechanism, since the authors found no correlation between varying concentrations of 
pamidronate and alendronate and the mRNA expression of OPG and RANKL (Kim et al., 
2002).  
A non-randomized, case controlled study by Chatterjee et al. (2012) evaluated the 
effects of pamidronate, after IV infusion, on the bone quality of a small group of 34 
patients that had been diagnosed with OOS due to either TM or TI. The investigators 
administered 1 mg/kg body weight of pamidronate to patients monthly for 3 years, 
combined with hormonal replacement therapy (HRT) due to low sex steroid levels in all 
participants (Chatterjee et al., 2012). They assessed the remodeling and microarchitecture 
of patients’ bone tissue before and after treatment with pamidronate, using a DEXA scan, 
type 1-collagen biochemical bone markers (BBM) and histomorphometric measurements 
(Chatterjee et al., 2012). Following treatment, the study demonstrated a significant 
improvement in BMD at the spine and hip in TM patients, compared to the control group 
(Chatterjee et al., 2012). 
This study also discovered disparities in response to pamidronate treatment 
between TM patients and patients diagnosed with TI (Chatterjee et al., 2012). Before 
treatment with pamidronate, histomorphometric measurements indicated that TM patients 
with OOS had a much higher bone turnover compared to TI patients (Chatterjee et al., 
2012). Following 3 years of treatment, measurements indicated a significant 
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improvement in bone volume for TM patients, and yet little change was detected in TI 
patients (Chatterjee et al., 2012). Evidently, Chatterjee et al. (2012) found that TM 
patients responded better to treatment than TI patients, an observation even more 
apparent when comparing levels of improvement for BMD, specifically at the spine. TM 
patients exhibited substantial increases in BMD at both the spine and hip, but in TI 
patients, improvement was only observed in hip BMD (Chatterjee et al., 2012). This data 
suggests that the type of bone disease and its progression varies depending on whether 
the thalassemia disease subset is TM or TI, further implying that having one subset over 
the other drastically affects an individual’s clinical response to treatment with 
bisphosphonates (Chatterjee et al., 2012). Accordingly, it is imperative that an 
individually-catered approach is used when clinicians and patients consider treatment 
options for the management of thalassemia-associated OOS. 
Lastly, there are a few concerns that pamidronate therapy could lead to significant 
adverse events in patients. One study by Zarychanski and colleagues (2006) specifically 
found that pamidronate medication was the lone variable common to all 12 patients 
diagnosed with osteonecrosis of the jaw. These patients were being given pamidronate in 
response to bone-associated diseases, including breast carcinoma, renal cell carcinoma, or 
multiple myeloma (Zarychanski et al., 2006). The authors reported that the treatment 
duration ranged anywhere from 12 to 77 months before jaw osteonecrosis was observed, 
and that discontinuation of the therapy was unsuccessful in reversing the pathology of the 
disease in these patients (Zarychanski et al., 2006). Therefore, clinicians should ensure 
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that their patients are well-informed about the possibility of suffering jaw osteonecrosis 
prior to commencing therapy with pamidronate.  
 
Neridronate 
Neridronate is an amino-bisphosphophonate that can uniquely be administered as 
either an intravenous or intramuscular formulation in human beings (Gatti et al., 2013). It 
is commonly indicated for the treatment of osteogenesis imperfecta (Figure 7) and 
Paget’s disease of bone, however neridronate is gradually being proven effective in other 
analogous pathologies, including postmenopausal osteoporosis, glucocorticoid-induced 
osteoporosis (GIO), complex regional pain syndrome type I (CRPS-1), periodontitis and 
thalassemia (Gatti et al., 2013).  
 
Figure 7. Treatment of Osteogenesis Imperfecta with Bisphosphonates. Vertebral 
bodies before (A) and after (B) a 14-month treatment with neridronate or pamidronate for 
a child with Type I osteogenesis imperfecta are shown. Figure taken from (Semler et al., 
2011). 
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Neridronate has much potential as a treatment option for BTM-induced OOS. It is 
a preferred bisphosphonate agent in cases where patients feel uncomfortable sitting 
upright and/or have experienced adverse effects, such as irritation or ulceration of the 
esophagus and stomach, from oral administration (Gatti et al., 2013). Furthermore, 
pharmacokinetic studies have demonstrated that bisphosphonates have a very low oral 
bioavailability, so consuming neridronate in place of other accessible bisphosphonates 
would offer the additional advantage of greater drug absorption in the patient (Graham et 
al., 1997). 
A Phase 2, randomized study by Forni et al. (2012) assessed the efficacy and 
safety of neridronate in a large cohort of adult patients with BTM- or TI-induced OOS, 
specifically by investigating its effects on BMD and back pain. Every three months, 54 
patients randomly selected for the trial group were treated with neridronate intravenously 
with vitamin D and calcium, while the 64 patients in the placebo group were given only 
the vitamin D and calcium for the duration of the study (Forni et al., 2012). After 6 
months of treatment, Forni et al. (2012) observed significant increases in BMD at the hip 
and lumbar spine for the trial group, especially in comparison to the placebo group. The 
authors also found that patients receiving neridronate not only tolerated the agent well, 
but also experienced less back pain after merely 3 months of treatment, consequently 
leading to a general reduction in analgesic use (Forni et al., 2012). This decrease in the 
consumption of analgesic drugs due to the therapy, coupled with the study’s concurrent 
finding that patients demonstrated a substantial decrease in hepatic transaminases, makes 
neridronate an especially favorable therapeutic option for BTM patients (Forni et al., 
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2012). BTM patients exhibit abnormal liver function and elevated levels of aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) due to iron overload or 
hepatitis infection from blood transfusions; by decreasing analgesic drug use, neridronate 
would hypothetically benefit the liver by greatly reducing these AST and ALT levels 
(Forni et al., 2012). 
 
Zoledronic Acid 
Zoledronic acid is the most potent amino-bisphosphonate available for the 
treatment of thalassemia-associated osteoporosis (Reid, 2003). The agent has been 
demonstrated through extensive research to be very effective in treating several central 
bone diseases, including post-menopausal osteoporosis and glucocorticoid-induced 
osteoporosis (GIO) (Reid, 2003). As a result, researchers have been increasingly 
conducting clinical trials to specially assess its safety and efficacy as a major therapeutic 
option for the management of OOS in TM patients. 
For example, a randomized, placebo-controlled trial by Voskaridou et al. (2006) 
tested the effects of zoledronic acid on the BMD, biochemical markers of osteoclast 
function, bone pain and fracture risk of BTM patients with OOS. The study evaluated 
three groups before and after testing, where each group followed a unique dosing regime 
throughout the trial: patients randomly placed in groups A and B received zoledronic acid 
through IV infusion at a dose of 4 mg, either every 6 months or every 3 months, 
respectively, and patients in group C received a placebo every 3 months for a total study 
period of one year (Voskaridou et al., 2006). Markedly, the doses given to both 
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zoledronic acid groups throughout the study greatly exceed the standard dose of 5 mg, to 
be administered once yearly via IV infusion, that is currently approved for post-
menopausal osteoporosis (Voskaridou et al., 2006; Reid et al., 2002). Nonetheless, 
Voskaridou et al. (2006) found that zoledronic acid was able to increase the BMD of the 
lumbar spine, as well as decrease bone resorption and osteoclast activity, in patients 
receiving 4 mg of the agent intravenously every 3 months, all without causing any severe 
adverse effects. Comparatively, group B, which received the same dose every 6 months, 
did not yield any changes in BMD by the end of the year-long trial, suggesting that the 
higher dose is actually required for there to be any effect in TM patients (Voskaridou et 
al., 2006).  
Notably, the authors followed up with the TM patients with OOS from this study 
after two years, post discontinuation of their treatment with zoledronic acid (Voskaridou 
et al., 2008). In this follow-up study, the authors observed that the BMD of the patients 
continued to increase up to 24 months beyond cessation of treatment, clearly indicating 
strong residual effects of the drug (Voskaridou et al., 2008). Voskaridou et al. (2008) 
were also able to confirm the safety of the bisphosphonate for up to 2 years after its 
discontinuation in patients with BTM-induced OOS, since no significant adverse effects, 
such as jaw osteonecrosis, which has been associated with pamidronate therapy 
(Zarychanski et al., 2006), were observed throughout the entire duration of both studies. 
Nevertheless, more evidence is needed and advised, through the conduction of additional 
recent, well-controlled and longitudinal studies, testing larger cohorts of TM patients, in 
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order to truly determine the ideal dosage and effective treatment regime that is safe for 
the management of TM-induced OOS. 
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POTENTIAL PHARMACOLOGICAL THERAPIES 
Although current therapies are being widely used by clinicians to support the 
management of BTM-induced OOS in their patients, a number of novel pharmacological 
agents are continually being tested in various stages of clinical trials. These emerging 
options for BTM patients include denosumab, calcitonin, strontium ranelate and 
teriparatide. Their efficacy, as demonstrated in recent trials, as well as any limitations are 
discussed below. 
 
Denosumab 
Denosumab is a human monoclonal IgG2 antibody with high specificity and 
affinity for the receptor activator of nuclear factor kappa B ligand (RANKL), a protein 
that is expressed by macrophages and osteoblasts and is member of the tumor necrosis 
factor (TNF) cytokine superfamily (Cummings et al., 2009). Normally, in a complex 
mechanism that aims to regulate human bone remodeling, RANKL binds to its receptor 
(RANK), which is expressed on the surface of osteoclast precursor cells, to promote 
osteoclast formation, activation, and survival (Boyce & Xing, 2008). Osteoprotegerin 
(OPG), another member of the TNF receptor superfamily, prevents this RANK/RANKL 
interaction by binding to RANKL and acting as a competitive inhibitor of RANK 
activation (Boyce & Xing, 2008). In BTM patients, this RANK/RANKL/OPG system is 
altered in significant favor of increased osteoblast dysfunction and enhanced osteoclast 
activity (Narayanan, 2013). Denosumab, which is considered to target the 
RANK/RANKL pathway like OPG, offers a means to counteract this imbalance in BTM 
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patients (Yassin et al., 2014). By preventing the interaction between RANK and RANKL 
on the osteoclast surface, this potent agent inhibits both osteoclast activity, as well as the 
maturation, differentiation and fusion of osteoclast precursors to form new mature 
osteoclasts, essentially leading to a substantial decrease in bone resorption (Yassin et al., 
2014). 
While studies for denosumab therapy are ongoing, initial research suggests that 
the antiresorptive agent has a lot of potential. Approved by the U.S. Food and Drug 
Administration (FDA) in 2010 for the treatment of osteoporosis in postmenopausal 
women, denosumab has been found to increase BMD as well as significantly reduce the 
risk of hip, vertebral and nonvertebral fractures in this demographic (Cummings et al., 
2009). Through a randomized, placebo-controlled trial, Cummings et al. (2009) 
subcutaneously administered the anti-resorptive agent to postmenopausal women at a 
dose of 60 mg every 6 months, for a total trial period of 3 years, and found no significant 
differences in adverse effects between subjects in the denosumab group and those in the 
placebo category. Another study by Smith et al. (2009) described similar results when 
investigating the effects of denosumab on BMD and fractures in men receiving androgen-
deprivation therapy (ADT) for nonmetastatic prostate cancer. In this double-blind, 
multicenter study, the researchers also found that denosumab administration led to a 
reduction in the incidence of new vertebral fractures and significant increase in BMD 
(Smith et al., 2009).  
Comparatively, in a recent uncontrolled before-and-after study, denosumab was 
administered subcutaneously to 30 young patients with BTM-induced OOS at a dose of 
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60 mg twice yearly for the duration of the 1-year trial (Yassin et al., 2014). Markedly, 
Yassin et al. (2014) found a strong correlation between denosumab administration and 
significant increases in BMD at the lumbar spine and right femoral neck of patients with 
BTM-induced OOS. The authors also noted reduced bone resorption, analogous to effects 
previously observed in post-menopausal women receiving ADT (Yassin et al., 2014). 
Denosumab is currently in phase 2 clinical trials for BTM-induced OOS (Giusti et al., 
2016). 
	  
Calcitonin 
Calcitonin is a physiologic, endogenous hormone and anti-resorptive agent, as it 
both inhibits and reduces the number of active osteoclasts, thereby preventing bone 
resorption, while simultaneously increasing the number of osteoblasts in order to 
encourage bone formation (Hegde et al., 2016). Extensive clinical research supports its 
use as a therapeutic option of osteoporotic patients. For example, a five-year, double-
blind, randomized and placebo-controlled trial by Chesnut et al. (2000) investigated the 
effects of salmon calcitonin nasal spray on postmenopausal women with spinal 
osteoporosis. The authors found that 200 IU of the agent by nasal spray was able to safely 
increase or normalize BMD, as well as significantly reduce the risk of new vertebral bone 
fractures (by 33% to 36%) in the subjects (Chesnut et al., 2000). Chesnut et al. (2000) 
also noted that calcitonin was well tolerated by the elderly women, as evident by the fact 
that barely any adverse effects were reported.  
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In a slightly older double-blind, placebo-controlled study, Lyritis et al. (1997) 
assessed patients with vertebral crush fractures, associated with osteoporosis. The authors 
of this study found that trial subjects treated with calcitonin experienced reduced pain, 
and were able to move and recover their locomotor skills sooner than those in the placebo 
group (Lyritis et al., 1997). Therefore, even though additional studies are needed to 
specifically determine the potential of calcitonin as a therapeutic option for patients with 
BTM-induced OOS, it is likely that the osteoclast inhibitor will prove highly beneficial in 
the future. 
 
Strontium Ranelate 
Strontium ranelate (SrR) is a currently approved alternative to treating 
osteoporosis in men and postmenopausal women (Giusti & Bianchi, 2015). Specifically, 
one study found SrR to effectively reduce fracture risk and increase BMD in 
postmenopausal osteoporotic women (Meunier et al., 2004). However, little clinical data 
exists on the agent’s effects in patients with BTM-induced OOS. Moreover, despite being 
recognized as an influence on several key regulators involved in bone metabolism as well 
as pathophysiology of BTM-induced OOS, including the IGF-1 and the RANKL/OPG 
system, the mechanism of action of SrR remains unclear (Giusti et al., 2016). Some 
preclinical studies have proposed that SrR acts by stimulating bone formation whilst 
simultaneously inhibiting bone resorption (Giusti & Bianchi, 2015). This reversal of the 
standard process of bone remodeling would correspondingly lead to a net increase in 
BMD and bone strength, as well as an overall reduction in fracture risk (Giusti & 
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Bianchi, 2015). However, according to a later study that compared the transiliac paired 
bone biopsies following oral treatment with SrR and alendronate, SrR did not exhibit 
adequate anabolic action on bone remodeling (Chavassieux et al., 2014). 
A notable study by Morabito et al. (2015) evaluated the effects of SrR on bone 
turnover markers, sclerostin levels, and BMD at the lumbar spine and femoral neck for 24 
postmenopausal female patients with BTM-induced OOS. In this randomized controlled 
trial, the subjects were either given 2 g or a placebo daily, in combination with vitamin D 
and calcium carbonate, and they were assessed at both baseline and after 24 months of 
treatment (Morabito et al., 2015). Markedly, the investigators found that, compared to the 
placebo group, lumbar spine BMD significantly increased in the SrR subjects after 
treatment (Morabito et al., 2015). They also observed considerable deviations in the bone 
turnover markers as well as reduced sclerostin levels, strictly in the SrR group (Morabito 
et al., 2015). While Morabito et al. (2015) did not observe a significant change at the 
femoral neck for any of the participants in the study, it is apparent that an actual increase 
in BMD only occurred in the group given SrR for 24 months (Figure 8). 
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Figure 8. Correlation between Strontium Ranelate and BMD. BMD measurements 
that were assessed at baseline and after 24 months of treatment with either strontium 
ranelate (SrR) or placebo in postmenopausal, female subjects are shown. Figure taken 
from (Morabito et al., 2015). 
 
Unfortunately, several recent concerns have been raised in regards to the safety of 
SrR for patients with a history of cardiovascular disease. A particular safety report by the 
Pharmacovigilance Risk Assessment Committee, which analyzed the safety findings of 
many new randomized clinical trials on SrR in both osteoporotic men and women, 
ultimately associated patients that were treated with SrR to an increased risk for 
cardiovascular disease (Giusti & Bianchi, 2015). However, research is still ongoing, with 
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one recent study on 40 postmenopausal osteoporotic women finding no statistically 
significant correlation between SrR and increased myocardial infarctions or 
thromboembolic events, or even alternations in markers of cardiovascular risk, following 
12 months of treatment (Atteritano et al., 2016). Nonetheless, patients and clinicians 
should be cautious when considering SrR for treatment, especially if a patient has a 
cardiac condition; since BTM patients run a greater risk of cardiac iron overload due to 
regular transfusions, other agents should probably be considered before SrR. 
 
Teriparatide 
Teriparatide (PTH 1—34) is a recombinant, short amino-terminal fragment of the 
parathyroid hormone (PTH) that is recognized as the only anabolic therapy currently 
approved for the treatment of osteoporosis, and that is known to promote new bone 
formation when given at low doses intermittently (Cipriani et al., 2012). It is considered 
to be one of the most effective treatments for glucocorticoid-induced osteoporosis (GIO) 
as well as fracture prevention in both men and postmenopausal women (Cipriani et al., 
2012).  
Unfortunately, data concerning the clinical use of this agent in patients with 
BTM-induced OOS in particular is severely lacking, and presently limited to single case 
reports. Specifically, one report by Tournis et al. (2015) explored the effects of 
teriparatide in an adult male patient with BTM-induced OOS, who received two trials of 
teriparatide treatment over an 8-year period. Since this patient was diagnosed with low 
BMD and multiple vertebral fractures, he reported having consumed alendronate, an 
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accepted bisphosphonate, for the past 3 years, in conjunction with regular blood 
transfusions and chelation therapy for BTM (Tournis et al., 2015). Accordingly, the 
patient was told to continue taking alendronate; however, following inadequate response 
to the agent after a year, he was switched to teriparatide for the first time, for 18 months 
(Tournis et al., 2015). Markedly, Tournis et al. (2015) found an initial decrease in BMD 
during the first 6 months of the teriparatide treatment, followed by a steadily increasing 
BMD, and eventually, significant increase by the 1 to 1.5-year mark of treatment with the 
agent, indicative of a delayed treatment response (Figure 9). After a subsequent 4-year 
interval with the administration of alendronate alone, the patient was given a second trial 
of teriparatide treatment due to an unforeseen hip fracture (Tournis et al., 2015). 
Importantly, the authors observed an immediate, substantial increase in both femoral 
neck and total hip BMD following this retreatment, especially compared to the first 
course of teriparatide that was administered to the patient (Tournis et al., 2015) (Figure 
9). These results suggest that retreatments with teriparatide may prove effective in the 
management of lifelong OOS in thalassemia patients, especially if these patients have 
developed resistance to other antiresorptive agents, such as denosumab or 
bisphosphonates (Tournis et al., 2015).  
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Figure 9. Changes in BMD from Sequential Treatment with Alendronate and 
Teriparatide. The BMD was measured at the total hip and femoral neck of the patient. 
The arrows in the graph represent the points at which first treatment with teriparatide, 
FTR, or retreatment with teriparatide occurred. Percent changes in bone formation, 
indicated by P1NP, amino-terminal propeptide of Type 1 collagen, and CTX, carboxy-
terminal collagen cross-links, are also shown in the bottom left and right of the figure, 
respectively. Figure taken from (Tournis et al., 2015). 
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While teriparatide has yet to be studied extensively for BTM-induced OOS, and 
the cellular mechanisms by which it stimulates bone formation are still unclear, much 
research has been published in support of its effectiveness in reducing the risk of bone 
fractures in postmenopausal women and men. Approved by the FDA for postmenopausal 
osteoporosis in 2002, teriparatide has been used in the United States for over 10 years in 
the treatment of osteoporosis for both men and women (Cipriani et al., 2012). However, 
Cipriani et al. (2012) emphasize that the FDA contraindicate the use of teriparatide in any 
patients with a history of osteosarcoma, risk for osteosarcoma, or children and/or 
adolescents with open epiphyses. Pregnancy and breastfeeding are also recommended by 
the FDA as contraindications to the agent, however these conditions have not been 
investigated with respect to teriparatide, so no data is currently available (Cipriani et al., 
2012).  
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DISCUSSION 
This review has examined a number of therapeutic options for TM-induced OOS. 
Some therapies are recommended as preventative measures to be used towards the onset 
of TM-induced OOS; others are currently the most accessible and well-tolerated in 
patients. Lastly, there are novel pharmacological agents that are still in various stages of 
clinical testing right now, however have a lot of potential in supporting the management 
of the disease in the near future. Although no single, remediable treatment option 
currently exists for TM-induced OOS, there are a wide range of options that can be used 
to manage the symptoms, that include back pain, and to prevent additional bone damage 
in patients. However, since the pathogenesis of TM-induced OOS remains complex and 
multifactorial, and considering the heterogeneous nature of the disease and differences in 
the clinical response among patients, an individualized, multidisciplinary approach is 
needed to determine the most suitable therapy. It is likely that each patient may require a 
carefully edited therapeutic treatment regime. 
Selecting the primary type of therapy for TM-induced OOS can become a very 
complicated process, as numerous factors must be considered before commencing any 
management regime. These variables include and are not limited to medical history, 
severity of OOS, prevalence or lack of concomitant secondary endocrine diseases, 
tolerance to medications administered orally, intravenously, intramuscularly or by nasal 
spray, lifestyle, and age. Therefore, the optimum approach to determining the best 
therapeutic option for a BTM patient with OOS would involve initially checking patient 
history and measuring all of his/her baseline traits, such as BMD, bone turnover markers, 
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liver enzyme measurements, sex hormone levels, and any additional markers indicative 
vulnerability to OOS-associated risk factors. If a patient is found to have a coexisting 
endocrine disease, such as diabetes mellitus or hypogonadism, which have the potential 
to negatively alter bone remodeling parameters, the condition should be treated as soon as 
possible.  
For a TM patient who is at the onset of the disease, or for whom the severity of 
bone loss is insignificant (i.e. minimal variations in BMD and bone turnover, no bone 
fractures), general preventative measures should be presented and reinforced. These 
measures include regular physical exercise, a healthy and nutritional diet, iron chelation 
therapy to prevent iron overload from blood transfusions, and adequate vitamin D and 
calcium intake.  
If the TM patient does not have a history of analgesic or substance drug abuse, 
bisphosphonates should certainly be considered as a first line therapy. Notably, 
bisphosphonates that can be administered by IV infusion or intramuscularly have been 
demonstrated in many recent studies as particularly effective at improving BMD in BTM 
patients, and they further provide a convenience that the other BPs lack. Intravenous 
administration of BPs does not require a patient to remain upright at the time of 
administration and they do not involve the added risk of causing irritation or 
inflammation to the esophagus or stomach lining that exists when using oral BPs. Two 
notable IV bisphosphonates, ranging in potency and safety, are currently being tested for 
the treatment of TM-induced OOS: neridronate and zoledronic acid. Zoledronic acid is 
more potent, but both agents offer more safety, have been demonstrated to alleviate back 
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pain, and can be administered in more ways than oral BPs like pamidronate. Considering 
all of these factors, neridronate should be considered for usage at the forefront of BTM-
induced OOS management. 
Significantly, one of the major limitations of using bisphosphonates as a primary 
form of therapy for BTM patients with OOS is the observation that most patients either 
develop resistance or need to incorporate interval “bisphosphonate-free” periods in order 
to avoid severe adverse effects that might result due to drug potency. Depending on the 
severity of OOS in a TM patient, these limitations can be addressed by combining 
therapy concerning a particular bisphosphonate with intermittent HRT or a weaker agent 
in the same family, such as alendronate or pamidronate, in comparison to zoledronic acid. 
Lastly, the results of the few studies published on new tentative treatments for 
BTM-induced OOS are encouraging, especially when evaluating the efficacy and safety 
of the monoclonal antibody, denosumab. As a potent, yet well-tolerated antiresorptive 
drug, denosumab has the potential to become an alterative to current BPs and first-line 
therapy for TM patients in the future. Teriparatide may prove useful for OOS patients 
with severe bone loss due to its potency, and strontium ranelate might be considered in 
patients who cannot be treated with BPs or denosumab. However, SrR use is largely 
discouraged, due to its potential for severe adverse effects, mainly involving the 
cardiovascular system. More research is needed to ensure the safety and efficacy of each 
of these pharmacological agents. 
In summary, as more insight is achieved in regards to the etiology and 
pathogenesis of TM-induced OOS, the complexity of the disease continues to underscore 
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the importance of a multidisciplinary, personalized approach to management. The 
ambiguity of the disease highlights the challenges that clinicians and researchers must 
confront and the numerous clinical factors they must consider in order to successfully 
determine and provide the most effective, yet safe form of therapy to a patient afflicted 
with this disease. It is important for the patient to be aware of what options are available 
and which therapy or combination of therapies is best suited to him or her. Therefore, 
future efforts should involve a more systemic characterization of the various baseline 
traits that are found in BTM patients. Understanding this heterogeneity and appreciating 
the diversity of symptoms and markers of TM-induced OOS in patients will prove critical 
for the success of future, targeting, individually-catered approaches.   
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